News coverage about CONMED Corporation (NASDAQ:CNMD) has trended somewhat positive this week, according to Accern Sentiment. Accern ranks the sentiment of news coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. CONMED Corporation earned a coverage optimism score of 0.21 on Accern’s scale. Accern also gave media headlines about the medical technology company an impact score of 46.3599192536702 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the media headlines that may have effected Accern Sentiment’s analysis:
- CONMED Corporation (CNMD) Given Hold Rating at KeyCorp (americanbankingnews.com)
- Edited Transcript of CNMD earnings conference call or presentation 2-Nov-17 8:30pm GMT (finance.yahoo.com)
- CONMED Corporation (CNMD) Earns Hold Rating from Piper Jaffray Companies (americanbankingnews.com)
- CONMED Corporation (CNMD) Announces Earnings Results (americanbankingnews.com)
- CONMED Corporation (CNMD) Issues FY17 Earnings Guidance (americanbankingnews.com)
Shares of CONMED Corporation (NASDAQ CNMD) traded up $1.01 during mid-day trading on Friday, reaching $53.37. The company had a trading volume of 102,436 shares, compared to its average volume of 88,131. The company has a debt-to-equity ratio of 0.83, a quick ratio of 1.57 and a current ratio of 2.62. The firm has a market capitalization of $1.49 billion, a price-to-earnings ratio of 30.41, a price-to-earnings-growth ratio of 3.35 and a beta of 0.66. CONMED Corporation has a 1 year low of $39.09 and a 1 year high of $54.47.
CONMED Corporation (NASDAQ:CNMD) last announced its quarterly earnings data on Thursday, November 2nd. The medical technology company reported $0.42 EPS for the quarter, topping the Zacks’ consensus estimate of $0.41 by $0.01. The firm had revenue of $190.10 million during the quarter, compared to analyst estimates of $187.13 million. CONMED Corporation had a return on equity of 8.43% and a net margin of 1.99%. The company’s revenue was up 2.9% on a year-over-year basis. During the same period last year, the company earned $0.41 earnings per share. analysts expect that CONMED Corporation will post 1.87 EPS for the current year.
The company also recently disclosed a quarterly dividend, which was paid on Thursday, October 5th. Investors of record on Friday, September 15th were given a $0.20 dividend. The ex-dividend date of this dividend was Thursday, September 14th. This represents a $0.80 dividend on an annualized basis and a yield of 1.50%. CONMED Corporation’s payout ratio is 145.45%.
A number of research firms recently issued reports on CNMD. Piper Jaffray Companies reaffirmed a “hold” rating and issued a $46.00 price target on shares of CONMED Corporation in a report on Friday. BidaskClub lowered CONMED Corporation from a “sell” rating to a “strong sell” rating in a research report on Sunday, August 20th. TheStreet upgraded CONMED Corporation from a “c+” rating to a “b-” rating in a research report on Thursday, August 3rd. Zacks Investment Research lowered CONMED Corporation from a “hold” rating to a “sell” rating in a research report on Friday, July 28th. Finally, Needham & Company LLC lifted their price objective on CONMED Corporation from $54.00 to $57.00 and gave the stock a “buy” rating in a research report on Thursday, July 27th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and one has assigned a buy rating to the stock. CONMED Corporation currently has a consensus rating of “Hold” and a consensus target price of $50.33.
In other news, Director Jo Ann Golden sold 3,000 shares of the business’s stock in a transaction dated Monday, August 14th. The stock was sold at an average price of $50.00, for a total transaction of $150,000.00. Following the completion of the transaction, the director now directly owns 19,782 shares in the company, valued at approximately $989,100. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 2.62% of the stock is currently owned by insiders.
CONMED Corporation Company Profile
CONMED Corporation is a medical technology company. The Company is engaged in the development, manufacturing and sale on a global basis of surgical devices and related equipment. The Company provides surgical devices and equipment for minimally invasive procedures. The Company’s products are used by surgeons and physicians in a range of specialties, including orthopedics, general surgery, gynecology, neurosurgery and gastroenterology.
What are top analysts saying about CONMED Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for CONMED Corporation and related companies.